Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Aug 16, 2022
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bellicum Pharmaceuticals, Inc
|
0
|
—
|
—
|
—
|
0
|
Aug 15
| |||||||
Bellicum Pharmaceuticals, Inc
|
0
|
—
|
—
|
—
|
0
|
Aug 16
| |||||||
Bellicum Pharmaceuticals, Inc
|
0
|
—
|
—
|
—
|
0
|
Aug 16
| |||||||
Clovis Oncology, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jun 10
| |||||||
Bellicum Pharmaceuticals, Inc
|
0
|
—
|
—
|
—
|
0
|
Dec 15
| |||||||
Clovis Oncology, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jun 4
| |||||||
Bellicum Pharmaceuticals, Inc
| 5K |
$4.00 | $19,998.50 |
∞
| 5K |
Mar 17
| |||||||
Bellicum Pharmaceuticals, Inc
|
0
|
—
|
—
|
—
|
0
|
Feb 3
| |||||||
Bellicum Pharmaceuticals, Inc
| 40K |
$1.25 | $50,000.00 | +150.60% | 66.56K |
Sep 10
| |||||||
Bellicum Pharmaceuticals, Inc
| 20K |
$0.99 | $19,780.00 | +304.83% | 26.56K |
Aug 21
| |||||||
Bellicum Pharmaceuticals, Inc
|
0
|
—
|
—
|
—
|
0
|
Jun 11
| |||||||
Clovis Oncology, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jun 6
| |||||||
Bellicum Pharmaceuticals, Inc
|
0
|
—
|
—
|
—
|
0
|
Feb 1
| |||||||
Clovis Oncology, Inc.
|
0
|
—
|
—
|
—
|
0
|
Oct 11
| |||||||
Clovis Oncology, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Bellicum Pharmaceuticals, Inc
|
0
|
—
|
—
|
—
|
0
|
Jul 2
| |||||||
Bellicum Pharmaceuticals, Inc
|
0
|
—
|
—
|
—
|
0
|
Jan 2
| |||||||
Bellicum Pharmaceuticals, Inc
|
0
|
—
|
—
|
—
|
0
|
Jan 30
| |||||||
Bellicum Pharmaceuticals, Inc
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||